Parkin and DJ-1 are two multi-functional proteins linked to autosomal recessive earlyonset Parkinson's disease (PD) that were shown to functionally interact by yet unknown mechanisms. We have delineated the mechanisms by which parkin controls DJ-1. Thus, parkin modulates DJ-1 transcription and protein levels via a signaling cascade involving p53 and the endoplasmic reticulum (ER)-stress-induced active X-box-binding protein-1S (XBP-1S). Parkin triggers the transcriptional repression of p53 while p53 down-regulates DJ1 protein and mRNA expressions. We show that parkin-mediated control of DJ-1 is fully p53 dependent. Furthermore, we establish that p53 lowers the protein and mRNA levels of XB-1S.
DJ-1 is implicated in approximately 1% of autosomal recessive FPD (Abou-Sleiman et al., 2003) and has been documented as a ubiquitously expressed and highly conserved protein present as a homodimeric complex in the cytoplasm (Bandopadhyay et al., 2004) . Several lines of evidence indicate that DJ-1 could act as an antioxidant (Taira et al., 2004) and could control mitochondrial function (Thomas et al., 2011 ), autophagy (Thomas et al., 2011 and pro-survival pathways (Giaime et al., 2010) . However, only fragmentary data concern the mechanisms by which DJ-1 transcription/expression is regulated and whether such regulation could be controlled by physiopathological stresses or cellular challenges.
Parkin is another important FPD-associated gene product that has been characterized as an ubiquitin-ligase (Shimura et al., 2000; Tanaka et al., 2001) . Interestingly, parkin was reported to interact physically with DJ-1 monomers in oxidative stress conditions (Moore et al., 2005b) . However, unlike expected from its ubiquitin ligase activity, parkin did not promote DJ-1 proteasomal degradation but instead, increased its cellular stability (Moore et parkin and DJ-1 could coordinately but independently contribute to mitochondrial function, the ability of parkin to interact with DJ-1 may likely have other functional consequences.
In this context, it is noteworthy that both parkin and DJ-1 have been associated to the ER-stress response also called unfolded protein response (UPR). Thus, parkin controls both endoplasmic reticulum and oxidative stresses (Takahashi et al., 2003) and interacts with Hsp70 and some members of the ERAD (ER-associated degradation) machinery, Ubc7 and
Ubc8 (Tanaka et al., 2001) . Directly linked to parkin-associated ligase activity, Imai and Colleagues showed that the Pael receptor that tends to be poly-ubiquitinated, unfolded and poorly soluble, in vivo, behaves as a parkin substrate (Imai et al., 2001) . However, unrelated to parkin enzymatic properties, oxidative stress indeed enhances the physical interaction between parkin and DJ-1 (Moore et al., 2005b) . We therefore questioned whether parkin could be functionally linked to DJ-1 in basal and ER-stress-induced conditions.
We show here that parkin up-regulates DJ-1 promoter trans-activation, mRNA levels and protein expression via a transcriptional cascade involving p53 repression and subsequent activation of ER-stress induced X-box-binding protein-1S (XBP-1S). Subsequently, XBP-1S physically interacts with DJ-1 promoter and thereby raises DJ-1 mRNA and protein levels.
Interestingly, parkin-mediated control of DJ-1 remained independent of its ubiquitin-ligase activity and is abolished by PD-related pathogenic mutations. Overall, our study is the first delineation of the molecular events linking parkin and DJ-1 and unravels a functional dialogue by which these two proteins could control ER-stress response in physiopathological conditions.
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Materials and Methods
Cell systems and Transfections
Telencephalon Specific Mouse 1 (TSM1), Mouse Embryonic Fibroblasts (MEF), Human Colorectal adenocarcinoma (HCT116), Human Embryonic Kidney 293 (HEK293) and SH-SY5Y human neuroblastoma cells were cultured in 5% CO 2 , in DMEM supplemented with 10% fetal calf serum containing penicillin (100U/ml) and streptomycin (50µg/ml).
TSM1 neurons expressing empty vector or wild-type HA-tagged parkin were obtained as described (Alves da Costa et al., 2003) . HEK293 cells stably expressing wild-type or mutated parkin were obtained after jetPRIME agent transfection (Polyplus) and geneticin selection for ten days. Immortalized mouse embryonic fibroblasts invalidated for the parkin, XBP-1, p19 arf and both p19 arf and p53 genes and HCT116 have been generously provided by Drs. T.
Dawson, L. Glimsher M. Roussel and B. Vogelstein. Transient transfection of SH-SY5Y, HEK293 were carried by means of either lipofectamine 2000 (Invitrogen) or jetPRIME reagent according to the manufacturer's instructions while parkin, p19 Arf-/-, p19 Arf-/-p53 -/fibroblasts were transfected by means of Nucleofactor TM kit (Amaxa Biosystems) as previously described (Pardossi-Piquard et al., 2005) .
Constructs and site-directed Mutagenesis
The cDNA of human parkin has been cloned in the pIRES2-EGFP-NEO vector (Clonetech). Wild-type human DJ-1 and p53 cDNAs were gifts from Dr. P. Heutink, and M.
Oren. Parkin mutagenesis was performed with the QuikChange II kit (Stratagene). 5'end truncated mouse XBP-1 promoter-luciferase constructs have been generated from the mouse XBP-1 full-length promoter-luciferase used as a template in PCR reactions. Primers used for the obtention of the 581, 438, 285 and 138 nucleotides promoter fragments are described in
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the Supplementary table 2 . These fragments were digested with SacI and HinDIII and subcloned in the pGL3 basic vector (Promega). The deletion of the putative p53 binding site on the wild-type mouse XBP-1 promoter was achieved with the XBP-1 forward and reverse primers described in supplementary table 2.
The deletion of the XBP-1 binding site of hDJ-1 promoter was obtained by three PCR steps: the first one using the GLprimer1 forward primer and the human DJ-1 deleted of XBP-1 binding site reverse primer. The second fragment was obtained using the GLprimer2 reverse primer with the human DJ-1 deleted of XBP-1 binding site forward primer. The right size products of the two first PCR were combined and mixed, then 10 PCR cycles were performed, the GLprimer1 and GLprimer2 were added and 25 more cycles were realized. Finally the human DJ-1 promoter deleted for the XBP-1 binding site was cloned in the pGL2-basic vector (Promega).
The p53 and DJ-1 promoter-luciferase constructs have been previously described (Ginsberg et al., 1990; Taira et al., 2001) . The unspliced and spliced mouse XBP-1 cDNA in pcDNA3-Flag, the pGL3-mouse XBP-1 promoter-luciferase, and the four XBP-1 shRNA-pSuper-puro were from Dr. L. Qi. shRNA (KD1, KD2 and SC) targeting human parkin have been engineered in our laboratory based on the published siRNA sequences (Veeriah et al., 2010) and inserted in the pSuper-GFP-neo vector according to the manufacturer's instructions (Oligoengine). All the primers (Eurogentec) used are described in Supplementary tables 1 and 2. All the constructs were verified by sequencing.
Western Blot Analysis
Cells were homogenized in lysis buffer (Tris-HCl, 10mM; pH7.5, containing NaCl (150mM), Triton X-100 (0.5%), deoxycholate (0.5%) and EDTA (5mM) and resolved on Journal of Cell Science Accepted manuscript 12% SDS-PAGE gel and wet-transferred to Hybond-C (Amersham Life science) membranes.
Immunoblottings were performed by means of the following antibodies: rabbit polyclonal anti-DJ-1 antibodies (MAB18257, Abcam), mouse monoclonal anti-parkin antibodies (MAB5512, Abcam), mouse monoclonal anti-p53 antibodies (Santa-Cruz Biotechnology), mouse monoclonal anti-GFP antibodies (Roche-applied-science), anti-XBP-1 antibodies (M-186, Santa-Cruz Biotechnology) or mouse monoclonal anti-actin antibodies (Sigma). Protein immunoreactivities were revealed with either an anti-rabbit peroxidase or an anti-mouse peroxidase (Jackson Immunoresearch) by electrochemoluminescence method (Roche Diagnostics S.A.S.). Chemiluminescence was recorded using a luminescence image analyzer LAS-3000 (Raytest), and quantification of images was performed using the FUJI FILM Multi Gauge image analyzer software.
DJ-1, p53 and XBP-1 promoter transactivations
The transcriptional activations of the human DJ-1, human p53 and mouse XBP-1 promoters in frame with luciferase (provided by Dr. H. Ariga; Dr. M. Oren and Dr. L. Qi, respectively) were measured after co-transfection of ß-galactosidase cDNA, in order to normalize transfection efficiencies (Promega). The protocol has been previously described (Alves da Costa et al., 2003) .
Real-time quantitative PCR
Total RNA from cells and mice brains were respectively extracted using the 
Chromatin Immunoprecipitation Assay (ChIP)
Wild-type and knockout XBP-1 MEF cells were seeded in three 150mm dishes and allowed to reach 70-80% confluence. Cells were fixed with formaldehyde, cross-linked and Journal of Cell Science Accepted manuscript 
Statistical Analysis
Statistical analyses were performed with GraphPad Prism software (GraphPad Software, San Diego, CA) by using either the unpaired Student's test for pair wise comparison or Newmann-Keuls multiple comparison tests for one-way ANOVA analysis of variance. *P<0.05; **P<0.01; ***P<0.001; ns, not statistically significant.
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Results
Parkin controls DJ-1 in cells and in mice brain.
We have examined the influence of the modulation of parkin (PK) levels on DJ-1.
Stably transfected TSM1 neurons overexpressing wild-type PK exhibit increased DJ-1 expression (+82% ± 23.4, Figure 1A ), promoter trans-activation (+41.6% ± 5.9, Figure 1B) and mRNA levels (+45.2 ± 10.4, Figure 1C ). The PK-associated up-regulation of DJ-1 has been corroborated by the examination of the influence of endogenous PK depletion on DJ-1 expression. Thus, parkin null fibroblasts (PK -/-) display lower DJ-1 expression (-49% ± 4.7 compared to control PK +/+ fibroblasts, Figure 1D ), promoter transactivation (-77% ± 4.9%, Figure 1E ) and mRNA levels (-30% ± 0.8, Figure 1F ). These results were similar in two distinct PK-deficient fibroblastic cell lines from distinct origins (data not shown). In order to rule out any artifactual effect linked to genetic manipulation, we have confirmed the latter set of data by the analysis of parkin depletion by a shRNA approach. As demonstrated in the Supplementary Figure S1 , two distinct parkin-directed shRNAs (KD1 and KD2, see methods)
that significantly decrease parkin expression (-53% ± 0.3 of scrambled (SC)-treated cells, for KD1 and -35% ± 1.3, for KD2; Supplementary Figure S1A ,B) concomitantly lower DJ-1 expression (-38% ± 2.1 of control value for KD1 and -41% ± 0.1 for KD2; Supplementary Figure S1B ) and promoter transactivation (-25% ± 1.2 for KD1, Supplementary Figure S1C ).
In order to examine the influence of parkin, in vivo, we have analyzed DJ-1 expression in brain samples derived from wild-type or parkin-null mice (Itier et al., 2003) . The depletion of parkin leads to the reduction of DJ-1 expression (-33% ± 2 of control PK +/+ brains, Figure   1G ), indicating that PK controls DJ-1 in both cellular models and in vivo.
The number of yet available parkin-associated human brain samples is extremely low and corresponds to a maximum of six worldwide. It is therefore very difficult to assess Journal of Cell Science Accepted manuscript whether PK mutations responsible for FPD also trigger decreased DJ-1 expression in pathogenic human brains. However, we had the opportunity to examine two of these samples in which a parkin missense mutation and deletion (FPD) have been identified (da Costa et al., 2009 ). We observed a diminution of DJ-1 expression (about 25% reduction versus control brains, data not shown). Although it is obviously hard to draw any firm conclusion, it remains that loss of function parkin mutation could also trigger DJ-1 reduction in human PD-affected brains.
PD-associated parkin mutations abolish PK-mediated control of DJ-1.
The human SH-SY5Y neuroblastoma cell line is a relevant dopaminergic cell model widely used in cell biology approaches of PD pathology. We have first confirmed that transient overexpression of PK in these cells also triggers increased DJ-1 expression (+44.4 ± 7.8 of control EV-transfected cells, Figure 2A ,B), promoter transactivation (+21% ± 1.5, Figure 2C ) and mRNA levels (+31% ± 1.7, Figure 2D ). Interestingly, two familial PDassociated mutations known to abolish (C418R) or preserve (K161N) the PK-linked ubiquitinligase activity both block these augmentations (Figure 2A -D). It should be noted that the transient transfection of PK mutants cDNAs led to various expressions ( Figure 2A ) that are not due to variability of transfection efficiency as evidenced by similar GFP expression (GFP coding sequence is harbored by the vector bearing PK sequences as described in the methods and under the control of the same promoter), but rather to faster catabolic rates of PK mutants as was described previously (da Costa et al., 2009; Hampe et al., 2006) . Therefore, we confirmed the above data in stably transfected HEK293 cells overexpressing wild-type, K161N-PK as well as another ubiquitin-ligase-deficient C441R-PK mutant. As was observed with transiently transfected cells (Figure 2A-D) , wild-type PK expression elicits an increase of DJ-1 expression (+86.7% ± 18.7% of mock-transfected cells, Figure 2E ,F), promoter transactivation (+123% ± 19.3 of mock-transfected cells, Figure 2G ) and mRNA levels (+72% ± 12.8, Figure 2H ), the increments of which were fully prevented by both mutations (Figure 2E-H) . Overall, the above data indicate that PK-mediated control of DJ-1 is not cell specific, occurs in dopaminergic cells as well as in vivo, and remains unrelated to PKassociated ubiquitin ligase activity.
DJ-1 is controlled by p53.
We recently documented a novel ubiquitin-ligase-independent function of PK that could act as a transcriptional repressor of the tumor suppressor p53 (da Costa et al., 2009 ).
Since the control of DJ-1 by PK was also independent of its ubiquitin-ligase activity, we have examined whether PK could control DJ-1 via p53. To address this question, we first examined the putative ability of p53 to control DJ-1. We took advantage of two cell models in which either p19 Arf or p19 Arf and p53 genes had been invalidated. The depletion of p19 Arf allows the analysis of the involvement of p53 in cell death without interference with p53-associated contribution to cell cycle control (Weber et al., 2000) . In Figure 3 , the comparison of p19 Arf-/-(white bars) and p19 Arf-/-p53 -/-(black bars) indicates that the depletion of endogenous p53
(compare lanes marked -) induces an increase of DJ-1 expression (+43.7% ± 13.6 of control EV-transfected p19 Arf-/cells, Figure 3A ,B), promoter transactivation (+149.3% ± 37.4, Figure   3C ) and mRNA levels (+147% ± 32, Figure 3D ). Complementation of both p19 Arf-/and p19 Arf-/-p53 -/fibroblasts by p53 cDNA transfection (lanes marked + in Figure 3A -D) leads to a significant diminution of DJ-1 expression (-30.8% ± 3.7 of control EV-transfected p19 Arf-/cells, and -33.8% ± 4.1 of control EV-transfected p19 Arf-/-p53 -/cells, Figure 3A ,B), promoter transactivation (-37.1% ± 3.3, and -30.9% ± 8.1, Figure 3C ), and mRNA levels (-53% ± 2.1,
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and -57% ± 7.4, Figure 3D ). Interestingly, analysis of brain samples from age-matched mice in which the gene of p53 has been invalidated (p53 -/-) or not (p53 +/+ ), indicates an increase of DJ-1 protein expression (+95% ± 8.9 of control p53 +/+ brains, Figure 3E ) and mRNA levels (+27.6% ± 9.3, Figure 3F ).
In order to further confirm the influence of p53 on DJ-1, we took advantage of another cell system in which p53 expression was altered to examine DJ-1 expression. Thus, the human colorectal carcinoma cell line (HCT116 p53 -/-) is a p53 knockout cell line derived from HCT116-p53 +/+ by homologous recombination (Bunz et al., 1998) . Interestingly, here again, we observed an up-regulation of DJ-1 expression (+49.1% ± 12.7% of HCT116-p53 +/+ cells, Supplementary Figure S2A ) and promoter transactivation (+116% ± 13.8 of control HCT116-p53 +/+ cells, Supplementary Figure S2B ). The above set of data first excludes a cell-specific regulation of DJ-1 by p53 and clearly establishes that p53 down-regulates DJ-1 protein expression and mRNA levels both in vitro and in vivo.
PK-mediated control of DJ-1 is p53-dependent.
The above data showing the up-regulation of DJ-1 by PK and its down-regulation by p53, together with our previous demonstration that parkin transcriptionally repressed p53 (da Costa et al., 2009) led us to envision that PK-associated increase of DJ-1 expression could occur through PK-mediated repression of p53. As previously established (da Costa et al.,
2009), stably transfected TSM1 neurons expressing wild-type PK exhibit drastically lower p53 expression (-81% ± 3 of control mock-transfected neurons, Figure 4A ). Thus, we examined the contribution of p53 by assessing the influence of endogenous p53 depletion on PK-mediated increase of DJ-1. We first observed that p19 Arf-/fibroblasts expressing PK cDNA exhibit an increased DJ-1 expression (+90.5% ± 23 of EV-transfected p19 Arf-/cells
(compare white bars), Figure 4B ,C), promoter transactivation (+56% ± 11, Figure 4D ) and mRNA levels (+91.9% ± 57.7, Figure 4E ). This shows that fibroblasts containing endogenous p53 respond to PK cDNA transfection and exhibit expected PK-mediated augmentation of DJ-1. As expected from above-described data, we confirmed that p19 Arf-/-p53 -/cells display increased DJ-1 expression, promoter transactivation and mRNA levels ( Figure 4B and compare white and black bars marked (-) in Figure 4C , D and E, respectively), and that they remained totally unaffected by PK cDNA transfection (see Figure 4B and compare black bars marked (+) and (-) in Figure 4C -E). This set of experiments demonstrates that parkinmediated regulation of DJ-1 is abolished by p53 depletion and thus, fully dependent of p53.
DJ-1 transcription is controlled by ER stress via the transcription factor XBP-1.
Based on our observation that p53 lowers DJ-1 promoter activity and mRNA levels ( Fig.3) , and sticking with the well characterized function of p53 as a transcription factor, we have performed an in silico study to search for putative p53 consensus binding sites in the human DJ-1 promoter. We did not delineate any fully conserved consensus site recognized by p53. We identified some putative partially conserved sites that we have mutated. However, none of the mutations tested affected p53-mediated control of DJ-1 promoter transactivation (data not shown), meaning that an additional molecular intermediate in the cascade linking PK and DJ-1 remained to be identified.
Interestingly, we identified a highly conserved XBP-1 binding site motif close to the transcription start site of different DJ-1 promoter sequences including human (h.DJ-1) and mice (m.DJ-1) species (see Figure 5A ). XBP-1 is a well-characterized protein activated by the Unfolded Protein Response (UPR or ER stress) (Yoshida et al., 2001) . Therefore, we envisioned the possibility that XBP-1 could be the missing link of the cellular machinery Journal of Cell Science Accepted manuscript functionally connecting PK and DJ-1. As a first attempt to study XBP-1 contribution to DJ-1 expression, we have first examined parkin, p53 and DJ-1 expressions responsiveness to an ER-stress. The treatment with a classical ER stress-inducer, thapsigargin (TPS) triggers an increase of parkin (+151% ± 24.2 of control untreated cells, Figure 5B ) and DJ-1 protein levels (+52% ± 19, Figure 5C ) as well as a reduction of the promoter activity of p53 (-49% ± 2.3, Supplementary Figure S3 ). These observations were fully in line with our hypothesis of an involvement of XBP-1 as a cellular intermediate between PK and DJ-1.
We have taken advantage of a cell model in which the Xbp-1 gene has been genetically invalidated (see XBP-1 expression in XBP-1 -/-(X -/-) cells in Supplementary Figure S4) to directly test the capability of XBP-1 to control DJ-1. XBP-1 depletion triggers a decrease of DJ-1 protein expression (-87% ± 0.6 of control XBP-1 +/+ cells, Figure 5D ), promoter transactivation (-72% ± 0.6, Figure 5E ) and mRNA levels (-76% ± 3.3, Figure 5F ). The depletion of XBP-1 by a siRNA approach confirmed the control of DJ-1 by XBP-1. Thus, two sets of siRNA (si1 and to a lesser extent, si2 siRNA, see Supplementary Figure S4 ) that lower XBP-1 also reduce DJ-1 expressions by about 26%.
Data derived from XBP-1 genetic manipulation experiments were further confirmed by a pharmacological approach. Thus, XBP-1 is activated by an unconventional mRNA splicing by the endonuclease IRE-1α in response to ER stress (Yoshida et al., 2001) .
Recently, one compound (referred to as 4µ8C thereafter) aimed at blocking IRE1-mediated splicing of XBP-1 and, as a consequence, interfering with XBP-1 function has been designed (Cross et al., 2012) . As shown in Supplementary Figure S5 , TPS-induced cellular stress reveals a XBP-1 spliced-like immunoreactive protein ( Supplementary Figure S5A) , the production of which is abolished in XBP -/cells and interestingly, totally prevented by 4µ8C in XBP +/+ cells (Supplementary Figure S5A) . It should be noted that 4µ8C did not affect unspliced XBP-1 (XBP-1U) in basal conditions (Supplementary Figure S5B , middle gel). Figure S5D) . Interestingly, 4µ8C also dose-dependently reduces DJ-1 protein expression (-31.6 ± 10.3, Figure 5G ) and lowers DJ-1 promoter transactivation (-63.7 ± 4.5, Figure 5H ) and mRNA levels (-27.5 ± 5.4, Figure 5I ).
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In order to definitely prove the direct transcriptional regulation Figure S5B , upper gel and the 4µ8C-sensitive XBP-1 mRNA auto-activation in basal conditions (not shown). As expected from above-described data, the spliced form (black bar, wt lane) but not the inactive form (grey bar, wt lane) of XBP-1 increased the transactivation of DJ-1 promoter (+157% ± 30.9, n=12, P<0.001; Figure 6A ). Interestingly, the mutation disrupting the consensus binding site of XBP-1 promoter completely abolished the responsiveness of the DJ-1 promoter to spliced XBP-1-mediated activation (compare black bars, Figure 6A ).
Finally, we have performed chromatin immunoprecipitation (ChIP) experiments to determine if XBP-1 physically interacted with the mouse DJ-1 promoter. The motif corresponding to the XBP-1 consensus binding site is located at position -444 to -439 from the TSS of DJ-1 promoter (see Figure 6B , upper scheme). We thus designed a couple of Journal of Cell Science Accepted manuscript primers covering the region -444 and -439 to examine the interaction of endogenous XBP-1 with the mouse DJ-1 promoter. As indicated in Figure 6B (lower panel), selective immunoprecipitation of XBP-1 leads to the amplification of a specific DJ-1-associated fragment in XBP-1 +/+ (X +/+ ) cells (compare lanes IgG control versus α-X). This fragment was absent when the immunoprecipitation was performed in XBP-1 -/-(X -/-) cells (compare lanes α-X in X +/+ and X -/cells). Overall, the above-data all concur to firmly support the view that endogenous XBP-1 directly and specifically interacts with, and up-regulates DJ-1 promoter.
XBP-1 is controlled by p53 and parkin.
In order to reconcile the fact that PK and p53 inversely modulate DJ-1 together with our observation that XBP-1 could up-regulate DJ-1, we have further examined the ability of parkin and p53 to control XBP-1. First, we show that the overexpression of p53 in SH-SY5Y cells represses the transactivation of the XBP-1 promoter (-41.6% ± 4.5, Supplementary Figure S6 ). Conversely, p53 depletion leads to increased XBP-1S expression in both basal (compare lanes p19 Arf-/and p19 Arf-/-p53 -/in upper gel, Figure 7A ) and TPS-induced (compare lanes p19 Arf-/and p19 Arf-/-p53 -/in lower gel; +133 % ± 34.1 of control p19 Arf-/cells, Figure   7B ) conditions. Clearly, the lack of p53 also increases XBP-1 promoter transactivation (+576% ± 81.8, (Prom) Figure 7C ) and mRNA levels (+61% ± 24, Figure 7C ). The regulation of XBP-1 promoter by p53 was confirmed in HCT116 p53 -/cells that also display higher XBP-1 promoter activity (+32% ± 6.4 of control HCT116 p53 +/+ cells, Supplementary Figure   S2C ). Finally, we have also established that the mRNA levels of XBP-1 are increased in p53 knockout mice brains (+80.8% ± 22 of control wild-type brains, Figure 7D ). Therefore, p53
behaves as a repressor of XBP-1 promoter transactivation in cells and in vivo.
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In agreement with the above-described data, the invalidation of the parkin gene triggers a significant reduction of XBP-1S expression (-31.9% ± 3.6 of control PK +/+ cells, Figure 7E ,F), promoter transactivation (-56% ± 2.4, Figure 7G ) and mRNA levels (-68% ± 3.3, Figure 7G ). We have also demonstrated that mRNA levels of XBP-1 are lowered in PKdeficient mice brain (-41% ± 18, Figure 7H ). The influence of PK on XBP-1S is therefore similar to the effect of PK on DJ-1. As a matter of fact, wild-type PK increases XBP-1 promoter transactivation (+143.1% ± 7, Supplementary Figure S7A ) and mRNA levels (+41.6 ± 4.3, Supplementary Figure S7B ). Interestingly, this phenotype was fully abolished by both ubiquitin-deficient and ubiquitin-active PK mutants.
In order to examine whether parkin-associated control of DJ-1 was fully dependent of XBP-1S, we pharmacologically blocked the activity of XBP-1S in cells devoid of endogenous parkin. We show that, in both basal ( Figure 8A ) and thapsigargin ( Figure 8B) indicates that most of parkin-mediated control of DJ-1 indeed requires XBP-1.
Discussion
The etiology of PD is complex and several cellular dysfunctions appear to underlie the neurodegenerative process occurring in this disease. Particularly significant is the observation of PD-related alterations of the ubiquitin-proteasome system that likely account for aberrant protein degradation and therefore, subsequent accumulation and aggregation as revealed by intracytoplasmic inclusions called Lewy bodies. Directly linked to these observations, the Journal of Cell Science Accepted manuscript activation of the unfolded protein response (UPR) also called endoplasmic reticulum-stress (ER-stress) has been consistently documented in PD-related cellular model (Ryu et al., 2002) as well as in PD-affected brain (Hoozemans et al., 2007) . Thus, this cellular response aims at regulating the overload of toxic abnormally folded proteins by inducing ER-resident chaperone proteins and by promoting their degradation (Ron and Walter, 2007) . The latter process is therefore a key event and alterations of proteins or enzymes linked to ubiquitinmediated proteasomal degradation are likely detrimental and central to PD development.
Parkin is a 52 kDa protein responsible for most of juvenile autosomal recessive forms (AR-JP) of PD. The structural features of this protein indicated that parkin could be involved in proteasomal degradation of ubiquitinated substrates. Thus, parkin harbors a N-terminal domain that displays homology with ubiquitin while its C-terminal moiety harbors RING motifs that are a structural hallmark generally exhibited by ubiquitin-ligases (Morett and Bork, 1999) . Indeed, parkin has been characterized as an E3-ubiquitin ligase, the activity of which is abolished by mutations associated with AR-JP (Shimura et al., 2000; Zhang et al., 2000) . Interestingly, the ability of parkin to prevent ER-stress has been linked to its capacity to trigger the degradation of a usually unfolded protein called Pael receptor (Imai et al., 2001) .
Parkin ubiquitinates Pael receptor in the ER and Pael receptor accumulates in AR-JP (Imai et al., 2001) . Thus, parkin-associated control of the UPR could be linked to its enzymatic properties and it was proposed that its defect could account for selective dopaminergic neurons death. However, it is noteworthy that it was recently documented that parkinassociated protection against ER-stress-induced cell death could be independent of the proteasomal machinery, indicating that parkin-related neuroprotection against ER-stress could not necessarily require its ubiquitin-ligase activity (Bouman et al., 2011) . In this context, it is interesting that we recently documented an additional parkin-associated function as a transcription factor (da Costa et al., 2009) . This agreed well with the preliminary description of a C-terminal IBR (In Between Ring) domain that indeed predicted a potential transcription factor activity for parkin (Morett and Bork, 1999) . Thus, we established that parkin transrepressed the transcription of the pro-apoptotic tumor suppressor p53 and that this led to neuronal neuroprotection (da Costa et al., 2009) . Whether this novel function could account for part of parkin-associated control of the UPR was therefore assessed.
Our study demonstrates that parkin controls the protein expression and promoter transactivation of DJ-1, another protein which, when mutated, accounts for a subset of autosomal recessive cases of PD (Bonifati et al., 2003) . By means of selective protein overexpression or gene inactivation in vitro and in vivo, we delineate a transcriptional cascade involving two intermediate transcription factors, namely p53 and the X-box-binding protein 1 (XBP-1). We establish that parkin represses p53 that acts as a repressor of XBP-1. Thereby, parkin activates XBP-1 that subsequently behaves as a strong transactivator of DJ-1 promoter transcription.
We show that human and mouse DJ-1 harbors a putative XBP-1-targeted consensus sequence, the mutation of which abolishes XBP-1-mediated DJ-1 promoter transactivation and we document a direct physical interaction of XBP-1 with the human (data not shown) and mouse DJ-1 promoter by ChIP approach (Fig.7B) . Interestingly, interfering with any of the actors of this molecular cascade modulates parkin-associated control of DJ-1.
The present study unravels several novel cellular processes and has strong implications for ER-stress-mediated cell death in PD. First, this is the initial demonstration of a UPR-related functional link between parkin and DJ-1, two proteins involved in autosomal recessive cases of PD. It is very interesting to note that this control occurs besides the The demonstration that XBP-1 could directly transactivate DJ-1 promoter delineates a novel mechanism by which XBP-1 could interfere with ER-stress-associated cell death. Thus, XBP-1 was previously shown to regulate the mRNA levels of several ER chaperone proteins, the induction of which corresponds to one of the main response elicited by the UPR.
Interestingly, DJ-1 has been shown to protect against both oxidative and reticular stress (Taira et al., 2004; Yokota et al., 2003) via the control of oxidative stress associated genes, like SOD (Nishinaga et al., 2005) and key apoptotic mediators like p53 and Pten (Giaime et al., 2010; Kim et al., 2005) and to behave as a chaperone protein (Lee et al., 2003) . Thus the present work also contributes to the understanding of one of the cellular responses leading to the enhancement of its chaperone, and thereby folding capacities, in response to ER-stress.
UPR is initially triggered by the binding of GRP78 to misfolded proteins. This leads to the release of PERK, a pancreatic ER kinase that, when freely recovered in the cells, is activated by homodimerization and catalytic auto-phosphorylation (Merksamer and Papa, 2010). Phopho-PERK then phosphorylates the initiation factor peIF2a that increases the transcription of ATF4 (Zhang and Kaufman, 2006) . Interestingly, parkin was recently shown to be transcriptionally modulated by ATF4 (Bouman et al., 2011) . Therefore, overall, our Recherche Médicale. This work was supported by the "Fondation pour la Recherche Médicale" and by the "Conseil Général des Alpes Maritimes". This work has been developed and supported through the LABEX (excellence laboratory, program investment for the future)
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